Form 4: Director Jeffrey Leiden Increases Stake in Odyssey

Director Jeffrey M. Leiden acquired 5,000 shares of Odyssey Therapeutics, Inc. and converted various preferred holdings into common stock.

Summary

• Director Jeffrey M. Leiden purchased 5,000 shares of common stock at $20 per share on May 8, 2026.
• The reporting person converted Series B, C, and D preferred stock into common stock on May 11, 2026, in connection with the company's initial public offering.
• The reporting person exercised warrants for common stock on a net exercise basis.
• The reporting person was granted a stock option for 626,220 shares with an exercise price of $18, vesting on May 7, 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the director's open-market purchase indicates personal capital commitment to the company's future.

Positives

• Director demonstrates confidence in the company by purchasing 5,000 shares on the open market.
• Conversion of preferred stock into common stock simplifies the capital structure following the IPO.

Negatives

• The company withheld 17 shares to cover the exercise price of warrants, representing a minor dilutionary event.

Risks

• Stock options are subject to continued service requirements through May 7, 2027.
• The value of the holdings is subject to market volatility following the initial public offering.

Future Outlook

The director's acquisition and option grant suggest a long-term commitment to the company's growth post-IPO, with options vesting in one year.

Management Comments

• The reporting person is a managing member of Racing Beach Ventures LLC and may be deemed to have beneficial ownership of the securities held by that entity.

Industry Context

StockSavvy.ai notes that insider buying following an IPO is generally viewed as a positive signal of management alignment with shareholder interests in the volatile biotech sector.

Comparison to Industry Standards

• The conversion of preferred stock to common stock is a standard procedure for biotech companies transitioning from private to public status.
• The use of net exercise for warrants is a common practice to minimize cash outlay for insiders.

Related Party Transactions

• Securities held by Racing Beach Ventures LLC, where the reporting person is a managing member.

Stakeholder Impact

• Shareholders may view the director's purchase as a vote of confidence in the company's post-IPO valuation.

Next Steps

• Vesting of 626,220 stock options on May 7, 2027.

Key Dates

Recommendation

While insider buying is positive, the filing reflects standard post-IPO housekeeping and incentive alignment rather than a fundamental shift in company strategy or performance.

Keywords

ODTX, Odyssey Therapeutics, Insider Trading, Form 4, Biotech, IPO